Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike
Principle: SARS-CoV-2 Spike pseudovirus infects 293T/ACE2 cells after incubation with the test antibody or serum. The pseudovirus neutralization inhibition rate of the tested antibody or serum can be calculated based on the luciferase/GFP luminescence value.
Capital equipment required: Yes
Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike is used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV2 spike protein. Pseudovirus display an antigenically-correct spike protein pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core.
Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike is capable of a single round of infection and carries a genome that expresses luciferase optical reporter gene upon infection. Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike are produced in HEK-293T cells using three separate plasmids, encoding the spike protein, a lentiviral gag polyprotein, and a reporter gene.
Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike are created using a second-generation lentiviral system with components that are highly unlikely to recombine to produce a fully infectious virus (requiring 3 separate recombination events to do so).
However, lentiviruses are capable of genomic integration, and pseudovirus is derived from biological materials so should be handled with caution within a BSL2 or enhanced BSL2 laboratory environment.
- Used in SARS-CoV-2 Pseudovirus Neutralization Assay.
- Safe in a BSL-2 environment.
- High infectivity titer
- Quantitative luciferase/GFP read-out
- Quality-controlled production for use as a critical reagent
Creative Diagnostics view full details
Website: Visit Website